KBC Group’s Boston Scientific BSX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$152M Sell
2,420,506
-623,879
-20% -$49.9M 0.38% 47
2025
Q4
$290M Buy
3,044,385
+84,768
+3% +$8.31M 0.66% 23
2025
Q3
$289M Buy
2,959,617
+297,044
+11% +$30.8M 0.69% 20
2025
Q2
$286M Buy
2,662,573
+419,460
+19% +$42.4M 0.77% 18
2025
Q1
$226M Sell
2,243,113
-137,408
-6% -$13.8M 0.7% 22
2024
Q4
$213M Buy
2,380,521
+41,720
+2% +$3.67M 0.59% 25
2024
Q3
$196M Buy
2,338,801
+457,383
+24% +$36.1M 0.59% 24
2024
Q2
$145M Buy
1,881,418
+153,645
+9% +$11.2M 0.44% 37
2024
Q1
$118M Sell
1,727,773
-119,912
-6% -$7.71M 0.38% 57
2023
Q4
$107M Sell
1,847,685
-339,983
-16% -$18.1M 0.38% 59
2023
Q3
$116M Buy
2,187,668
+45,697
+2% +$2.4M 0.47% 44
2023
Q2
$116M Sell
2,141,971
-648,629
-23% -$33.9M 0.48% 46
2023
Q1
$140M Sell
2,790,600
-100,900
-3% -$4.76M 0.59% 35
2022
Q4
$134M Sell
2,891,500
-1,076,834
-27% -$46.6M 0.65% 30
2022
Q3
$154M Buy
3,968,334
+240,315
+6% +$9.64M 0.8% 23
2022
Q2
$139M Buy
3,728,019
+441,604
+13% +$18M 0.69% 32
2022
Q1
$146M Buy
3,286,415
+357,349
+12% +$15.5M 0.58% 40
2021
Q4
$124M Buy
2,929,066
+547,827
+23% +$23M 0.41% 61
2021
Q3
$103M Sell
2,381,239
-1,819,523
-43% -$80.5M 0.38% 65
2021
Q2
$180M Buy
4,200,762
+942,612
+29% +$39.7M 0.32% 71
2021
Q1
$126M Sell
3,258,150
-3,776
-0.1% -$143K 0.26% 92
2020
Q4
$645M Sell
3,261,926
-145,692
-4% -$5.25M 0.28% 88
2020
Q3
$130M Buy
3,407,618
+260,882
+8% +$10.1M 0.38% 64
2020
Q2
$110M Buy
3,146,736
+1,691,273
+116% +$60.9M 0.37% 59
2020
Q1
$47.5M Buy
1,455,463
+409,999
+39% +$16M 0.4% 54
2019
Q4
$47.3M Buy
1,045,464
+129,912
+14% +$5.44M 0.3% 71
2019
Q3
$37.3M Sell
915,552
-217,666
-19% -$9.22M 0.27% 82
2019
Q2
$48.7M Buy
1,133,218
+151,966
+15% +$5.85M 0.38% 51
2019
Q1
$37.7M Buy
981,252
+68,112
+7% +$2.6M 0.31% 70
2018
Q4
$32.3M Buy
913,140
+101,885
+13% +$3.7M 0.36% 67
2018
Q3
$31.2M Buy
811,255
+103,084
+15% +$3.6M 0.24% 110
2018
Q2
$23.2M Sell
708,171
-2,686
-0.4% -$81K 0.2% 137
2018
Q1
$19.4M Sell
710,857
-88,997
-11% -$2.42M 0.18% 151
2017
Q4
$19.8M Sell
799,854
-249,827
-24% -$6.89M 0.17% 156
2017
Q3
$30.6M Buy
1,049,681
+28,579
+3% +$789K 0.28% 89
2017
Q2
$28.3M Sell
1,021,102
-38,181
-4% -$1.01M 0.27% 98
2017
Q1
$26.3M Buy
1,059,283
+31,393
+3% +$763K 0.24% 98
2016
Q4
$22.2M Buy
1,027,890
+172,049
+20% +$3.75M 0.22% 112
2016
Q3
$20.4M Buy
855,841
+205,213
+32% +$4.9M 0.24% 98
2016
Q2
$15.2M Sell
650,628
-16,073
-2% -$348K 0.22% 118
2016
Q1
$12.5M Sell
666,701
-19,967
-3% -$351K 0.21% 118
2015
Q4
$12.7M Buy
686,668
+81,203
+13% +$1.46M 0.23% 120
2015
Q3
$9.94M Sell
605,465
-123,665
-17% -$2.11M 0.2% 132
2015
Q2
$12.9M Buy
729,130
+448,190
+160% +$8.01M 0.17% 164
2015
Q1
$4.99M Sell
280,940
-543,988
-66% -$8.6M 0.06% 310
2014
Q4
$10.9M Sell
824,928
-56,553
-6% -$723K 0.13% 186
2014
Q3
$10.4M Buy
881,481
+256,768
+41% +$3.23M 0.36% 54
2014
Q2
$7.98M Buy
624,713
+217,768
+54% +$2.83M 0.09% 274
2014
Q1
$5.5M Sell
406,945
-240,288
-37% -$3.15M 0.09% 278
2013
Q4
$7.78M Buy
647,233
+148,853
+30% +$1.76M 0.12% 233
2013
Q3
$5.85M Buy
498,380
+156,828
+46% +$1.7M 0.09% 273
2013
Q2
$3.17M Buy
+341,552
New +$2.9M 0.06% 385

Other funds holding BSX

KBC Group's BSX Position: Q1 2026 in Review

KBC Group reduced its Boston Scientific (BSX) stake by 20% in Q1 2026, selling an estimated $49.9M and leaving 2,420,506 shares worth $152M. The position accounts for 0.38% of the portfolio, ranked #47.

KBC Group first reported a position in BSX in Q2 2013 and has held it in 52 quarters since. The position peaked at $645M in Q4 2020. 1,666 funds tracked by Wall St. Rank hold BSX as of Q1 2026.

  • KBC Group held 2,420,506 shares of Boston Scientific worth $152M as of Q1 2026.
  • KBC Group sold 623,879 Boston Scientific shares in Q1 2026, an estimated $49.9M.
  • Boston Scientific made up 0.38% of KBC Group's portfolio in Q1 2026, its #47 holding.
  • KBC Group first reported a position in Boston Scientific in Q2 2013 and has held it in 52 quarters since.
  • KBC Group's Boston Scientific position peaked at $645M in Q4 2020.
  • 1,666 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.

Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.